Because of a lapse in government funding, the information on this
website may not be up to date, transactions submitted via the
website may not be processed, and the agency may not be able to
respond to inquiries until appropriations are enacted. The NIH
Clinical Center (the research hospital of NIH) is open. For more
details about its operating status, please visit
cc.nih.gov. Updates
regarding government operating status and resumption of normal
operations can be found at
opm.gov.
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid MeSH Descriptor Data 2026
A stable prostaglandin endoperoxide analog which serves as a thromboxane mimetic. Its actions include mimicking the hydro-osmotic effect of VASOPRESSIN and activation of TYPE C PHOSPHOLIPASES. (From J Pharmacol Exp Ther 1983;224(1): 108-117; Biochem J 1984;222(1):103-110)
1998; 15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID was indexed under PROSTAGLANDIN ENDOPEROXIDES, SYNTHETIC 1978-97 & THROMBOXANE A2/analogs & derivatives 1983-97; (15S)HYDROXY-9ALPHA,11ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID and 9,11-EPOXYMETHANO-PGH2 were indexed under PROSTAGLANDINS H 1993-2003 & PROSTAGLANDIN ENDOPEROXIDES, SYNTHETIC 1986-1992
History Note
1998; use 15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID (NM) 1977-1997; for (15S)HYDROXY-9ALPHA,11ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID and 9,11-EPOXYMETHANO-PGH2 use PROSTAGLANDIN H2 (NM) 1992-2003
A stable prostaglandin endoperoxide analog which serves as a thromboxane mimetic. Its actions include mimicking the hydro-osmotic effect of VASOPRESSIN and activation of TYPE C PHOSPHOLIPASES. (From J Pharmacol Exp Ther 1983;224(1): 108-117; Biochem J 1984;222(1):103-110)